Skip to main content

Acute Stress Reaction

0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Spark Biomedical
Spark BiomedicalTX - Dallas
1 program
Sparrow HawkN/A
SPARK Biopharma
SPARK BiopharmaKorea - Seoul
1 program
Sparrow HawkN/A1 trial
Active Trials
NCT06390267Completed43Est. Jun 2025
Tonix Pharmaceuticals
Tonix PharmaceuticalsBERKELEY HEIGHTS, NJ
1 program
Cyclobenzaprine HClPHASE_21 trial
Active Trials
NCT06636786Recruiting180Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Tonix PharmaceuticalsCyclobenzaprine HCl
SPARK BiopharmaSparrow Hawk

Clinical Trials (2)

Total enrollment: 223 patients across 2 trials

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

Start: Mar 2025Est. completion: Sep 2026180 patients
Phase 2Recruiting

Effect of Transcutaneous Auricular Neurostimulation on Cognitive Performance in a Laboratory Model of Acute Stress Reaction

Start: Nov 2024Est. completion: Jun 202543 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 223 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.